Lung Cancer Drug Could Be 'Game-Changer'

Roche drug more effective on smokers than non-smokers: study
By Evann Gastaldo,  Newser Staff
Posted Sep 30, 2013 9:43 AM CDT
Lung Cancer Drug Could Be 'Game-Changer'

An experimental drug is actually more effective against lung cancer in patients who smoke than those who never have, Reuters reports. MPDL3280A, a Roche drug, is "great news for lung cancer patients," who are notoriously difficult to treat, researchers say; one oncologist says early-stage trials suggest it is "definitely a game-changer." In 53 patients with non-small cell lung cancer (NSCLC) tumors, 23% saw their tumors get smaller. But 26% of smokers saw their tumors respond, compared to just 10% of those who had never smoked.

"Bingo, this is the first targeted agent (drug) that shows more activity in smokers than in non-smokers," says the lead researcher. Why? The drug targets PD-L1, a protein that tumors use to manipulate T-cells in the immune system. The cells go inactive, and the tumors grow. MPDL3280A, an engineered antibody, blocks PD-L1; the T-cells awaken, grow, and multiply as they attack the cancer. The drug worked best on patients with higher levels of PD-L1, Bloomberg reports. Smokers have more genetic mutations in their tumors than non-smokers, and researchers think that's why their immune systems might respond more vigorously. Merck and Bristol-Myers Squibb are working on similar immunotherapy drugs, and Roche is looking into the possibility that its drug could treat other cancers. (Read more lung cancer stories.)

We use cookies. By Clicking "OK" or any content on this site, you agree to allow cookies to be placed. Read more in our privacy policy.
Get the news faster.
Tap to install our app.
Install the Newser News app
in two easy steps:
1. Tap in your navigation bar.
2. Tap to Add to Home Screen.